This site is intended for healthcare professionals
News

New data from HGB-206 study show near elimination of sickle cell disease-related vaso-occlusive crises by LentiGlobin gene therapy and plans to file at FDA in 2021 .- bluebird bio.

Read time: 4 mins
Last updated:15th Jun 2020
Published:13th Jun 2020
Condition: Sickle Cell Disease
Type: drug
Register for free exclusive healthcare eLearning resources


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest